MeiraGTx Holdings
Market Cap
US$678.5m
Last Updated
2021/01/24 00:42 UTC
Data Sources
Company Financials +
Executive Summary
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and fair value.
Share Price & News
How has MeiraGTx Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MGTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MGTX's weekly volatility (10%) has been stable over the past year.
Market Performance
7 Day Return
-4.5%
MGTX
1.8%
US Biotechs
2.3%
US Market
1 Year Return
-14.1%
MGTX
45.9%
US Biotechs
23.8%
US Market
Return vs Industry: MGTX underperformed the US Biotechs industry which returned 45.9% over the past year.
Return vs Market: MGTX underperformed the US Market which returned 23.8% over the past year.
Shareholder returns
| MGTX | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.5% | 1.8% | 2.3% |
| 30 Day | -4.8% | 6.7% | 4.8% |
| 90 Day | 17.3% | 24.9% | 14.5% |
| 1 Year | -14.1%-14.1% | 48.3%45.9% | 26.6%23.8% |
| 3 Year | n/a | 23.3%16.6% | 45.0%35.4% |
| 5 Year | n/a | 58.9%46.7% | 126.2%101.0% |
Long-Term Price Volatility Vs. Market
How volatile is MeiraGTx Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
Is MeiraGTx Holdings plc (NASDAQ:MGTX) Popular Amongst Insiders?1 month ago | Simply Wall St
Are Insiders Selling MeiraGTx Holdings plc (NASDAQ:MGTX) Stock?2 months ago | Simply Wall St
MeiraGTx Holdings plc (NASDAQ:MGTX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their EstimatesValuation
Is MeiraGTx Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MGTX ($15.63) is trading below our estimate of fair value ($67.71)
Significantly Below Fair Value: MGTX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MGTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MGTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MGTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MGTX is good value based on its PB Ratio (3.4x) compared to the US Biotechs industry average (4.4x).
Next Steps
Future Growth
How is MeiraGTx Holdings forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
20.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MGTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MGTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MGTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MGTX's revenue (63.4% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: MGTX's revenue (63.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MGTX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has MeiraGTx Holdings performed over the past 5 years?
-13.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MGTX is currently unprofitable.
Growing Profit Margin: MGTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MGTX is unprofitable, and losses have increased over the past 5 years at a rate of 13.1% per year.
Accelerating Growth: Unable to compare MGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: MGTX has a negative Return on Equity (-29.6%), as it is currently unprofitable.
Next Steps
Financial Health
How is MeiraGTx Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: MGTX's short term assets ($217.9M) exceed its short term liabilities ($46.6M).
Long Term Liabilities: MGTX's short term assets ($217.9M) exceed its long term liabilities ($67.4M).
Debt to Equity History and Analysis
Debt Level: MGTX is debt free.
Reducing Debt: MGTX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MGTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MGTX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 15.9% each year.
Next Steps
Dividend
What is MeiraGTx Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MGTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MGTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MGTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MGTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MGTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
Alexandria Forbes (55 yo)
5.83yrs
Tenure
US$8,480,263
Compensation
Dr. Alexandria Forbes, Ph.D. serves as the Chief Executive Officer and President at MeiraGTx Holdings plc (formerly known as MeiraGTx Limited) since 2015. Prior to joining MeiraGTx, Dr. Forbes served as Se...
CEO Compensation Analysis
Compensation vs Market: Alexandria's total compensation ($USD8.48M) is above average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Alexandria's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.83yrs | US$8.48m | 3.12% $ 21.2m | |
| COO & CFO | 1.75yrs | US$7.47m | 2.15% $ 14.6m | |
| General Counsel & Secretary | 1.42yrs | no data | no data | |
| Chief Development Officer | 5.75yrs | US$2.25m | 1.01% $ 6.8m | |
| Chief Scientist & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Senior Vice President of Global Integration | no data | no data | no data | |
| Senior Vice President of Finance | 5.67yrs | no data | no data | |
| Senior Vice President of Risk & Internal Controls | 1.75yrs | no data | no data | |
| Senior Vice President of Manufacturing & Supply Chain | 2yrs | no data | no data | |
| Chief Medical Officer | 0.42yr | no data | no data |
1.9yrs
Average Tenure
57yo
Average Age
Experienced Management: MGTX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.83yrs | US$8.48m | 3.12% $ 21.2m | |
| Chief Scientist & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.58yrs | US$455.13k | 0.17% $ 1.2m | |
| Member of Scientific Advisory Board & Independent Director | no data | US$445.13k | 0% $ 0 | |
| Independent Director & Member of Scientific Advisory Board | no data | US$440.13k | 0% $ 0 | |
| Independent Chairman of the Board | 2.92yrs | US$498.72k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.58yrs | US$455.13k | 0.030% $ 201.4k | |
| Independent Director | 3.25yrs | US$385.75k | 0% $ 0 | |
| Independent Director | 1.92yrs | US$524.90k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.4yrs
Average Tenure
67.5yo
Average Age
Experienced Board: MGTX's board of directors are considered experienced (4.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.
Top Shareholders
Company Information
MeiraGTx Holdings plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: MeiraGTx Holdings plc
- Ticker: MGTX
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$678.532m
- Shares outstanding: 43.41m
- Website: https://www.meiragtx.com
Number of Employees
Location
- MeiraGTx Holdings plc
- 430 East 29th Street
- 14th Floor
- New York
- New York
- 10016
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MGTX | NasdaqGS (Nasdaq Global Select) | Yes | Ordinary Shares | US | USD | Jun 2018 |
| 328 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 2018 |
Biography
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, includ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/24 00:42 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.